# OnCo record mirdametinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/mirdametinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "mirdametinib" ;
  schema:name "Mirdametinib"@en ;
  schema:alternateName "PD0325901"@en, "PD 0325901"@en, "PD-0325901"@en, "Gomekli / Ezmekly" ;
  schema:description "Mirdametinib (Gomekli in the US, Ezmekly in Europe) is a MEK-blocking capsule or dispersible tablet for adults and children with neurofibromatosis type 1 whose plexiform neurofibromas cannot be removed surgically; it is the first such drug approved for adults."@en ;
  schema:url <https://onco.cc/drugs/mirdametinib/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Mirdametinib> ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/ezmekly>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=mirdametinib> ;
  onco:status "approved" ;
  onco:tag "ema-list" ;
  onco:modality "Small-molecule allosteric MEK1/2 inhibitor" ;
  onco:approval "US 2025: NF1 with symptomatic plexiform neurofibromas not amenable to complete resection, adults and children 2 and over (Gomekli)", "EU 2025: Symptomatic, inoperable plexiform neurofibromas in NF1, age 2 and over (Ezmekly, conditional)" ;
  onco:related <https://onco.cc/drugs/selumetinib/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/mek/> ;
  onco:companies <https://onco.cc/companies/springworks/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:trials <https://onco.cc/trials/nct06153173/>, <https://onco.cc/trials/nct07061951/>, <https://onco.cc/trials/nct07237100/> .